Tracking a successful DLBCL assault in Phase II, MorphoSys sets out to seize quick OK for MOR208
Encouraged by a breakthrough designation at the FDA and its latest batch of upbeat data from a Phase II study of its anti-CD19 antibody MOR208 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
